Company Analysis

Moderna, Inc. (MRNA)

Nasdaq: MRNA · Biological Products, (No Diagnostic Substances) · Cambridge, MA · filing with the SEC since 2016
Grade5.7
◀ Past 7.3● Present 6.0▶ Future 3.6
1 est.

Who runs Moderna, Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Bancel Stephane
Chief Executive Officer. First filing Dec 2018, latest Aug 7, 2026, 268 filings in all.
Officers reporting now
6
of 14 people with a filing in the last fifteen months
Directors reporting now
8
31 people on the record since 2018
Officerssales are open-market, Nov 9, 2025 to Nov 9, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Andres JuanChief Operating OfficerDec 2018Nov 9, 2026none
Hoge StephenPresidentDec 2018Oct 16, 20269 · $45.4M
Mock James MChief Financial OfficerSep 2022Oct 7, 20262 · $4.7M
Klinger Shannon ThymeChief Legal OfficerJun 2021Sep 8, 20263 · $1.4M
Bancel StephaneChief Executive OfficerDec 2018Aug 7, 20264 · $28.7M
Banque Soria EsterChief Commercial OfficerJun 2026Jul 7, 2026none
Directorssales are open-market, Nov 9, 2025 to Nov 9, 2026
NameRoleFirst filingLatest filingSales, 12 months
Mcdonnell Michael R.directorJul 2026Jul 10, 2026none
Afeyan NoubardirectorDec 2018May 22, 20262 · $1.1M
Horning SandradirectorMay 2020May 8, 2026none
Hussain AbbasdirectorOct 2024May 8, 20262 · $300,000
Nabel Elizabeth GdirectorDec 2018May 8, 2026none
Nader FrancoisdirectorDec 2019May 8, 2026none
Rubenstein David M.directorAug 2024May 8, 2026none
Tallett Elizabeth EdirectorJul 2020May 8, 2026none
Earlier names on the record22, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton MRNA · research, not advice